<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation and prevention of infections associated with anti-integrin monoclonal antibodies (mAbs) and S1P receptor modulators</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation and prevention of infections associated with anti-integrin monoclonal antibodies (mAbs) and S1P receptor modulators</h1>
<div class="graphic"><div class="figure"><div class="ttl">Evaluation and prevention of infections associated with anti-integrin monoclonal antibodies (mAbs) and S1P receptor modulators</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1">Medication</td> <td class="subtitle1">Effect on immune system</td> <td class="subtitle1">Associated infections<sup>*</sup></td> <td class="subtitle1">Pre-treatment testing<sup>¶</sup></td> <td class="subtitle1">Pre-treatment vaccinations<sup>Δ</sup></td> <td class="subtitle1">Comments</td> </tr> <tr> <td class="subtitle2_left" colspan="6">Anti-integrin monoclonal antibody</td> </tr> <tr> <td class="indent1">Vedolizumab</td> <td>Inhibits alpha-4-beta-7 integrin and prevents its binding to MAdCAM-1, leading to impaired migration of memory T cells to the gut mucosal endothelium.</td> <td>Bacterial: <ul class="decimal_heading"> <li>Tuberculosis and other mycobacterial infections</li> </ul> <p class="extra_spacing_top">Viral:</p> <ul class="decimal_heading"> <li>EBV and CMV</li> <li>PML (JCV reactivation)</li> </ul> </td> <td>Test for: <ul class="decimal_heading"> <li>TBI</li> </ul> </td> <td> <ul> <li>Routine age-appropriate vaccinations</li> <li>Pneumococcal vaccine(s)</li> <li>RZV</li> </ul> </td> <td> <ul> <li>Vedolizumab does not appear to reduce parenterally delivered vaccine responses, but the response to oral vaccines may be lower.</li> </ul> </td> </tr> <tr> <td class="indent1">Natalizumab</td> <td>Inhibits alpha-4-beta-1 integrins, preventing it from binding to VCAM, leading to the inhibition of leukocyte migration to site of infection (including the CNS).</td> <td>Bacterial: <ul class="decimal_heading"> <li>Tuberculosis and other mycobacterial infections</li> </ul> <p class="extra_spacing_top">Viral:</p> <ul class="decimal_heading"> <li><strong>PML (JCV reactivation)</strong></li> <li>HBV</li> <li>HCV</li> <li>EBV and CMV</li> <li>Herpes zoster virus and HSV</li> </ul> <p class="extra_spacing_top">Fungal:</p> <ul class="decimal_heading"> <li>Cryptococcal infection</li> <li>Aspergillosis</li> </ul> </td> <td>Test for: <ul class="decimal_heading"> <li>TBI</li> <li>HBV</li> <li>HCV</li> <li>JCV<sup>◊</sup></li> </ul> </td> <td> <ul> <li>Routine age-appropriate vaccinations</li> <li>Pneumococcal vaccine(s)</li> <li>RZV</li> </ul> </td> <td> <ul> <li>Live vaccines should not be administered during the course of treatment nor up to 4 months after stopping therapy.</li> </ul> </td> </tr> <tr> <td class="subtitle2_left" colspan="6">Sphingosine-1-phosphate (S1P) receptor modulator</td> </tr> <tr> <td class="indent1">Fingolimod<sup>§</sup></td> <td>Inhibits S1P and prevents T cell migration from lymph nodes.</td> <td>Bacterial: <ul class="decimal_heading"> <li>Tuberculosis and other mycobacterial infections</li> </ul> <p class="extra_spacing_top">Viral:</p> <ul class="decimal_heading"> <li><strong>Herpes zoster virus</strong></li> <li>HSV</li> <li>PML</li> <li>Human herpesvirus 8-associated tumors</li> </ul> <p class="extra_spacing_top">Fungal:</p> <ul class="decimal_heading"> <li>Cryptococcal infection</li> </ul> </td> <td>Test for<sup>¥</sup>: <ul class="decimal_heading"> <li>TBI</li> <li>HBV</li> <li>HCV</li> </ul> </td> <td> <ul> <li>Routine age-appropriate vaccinations</li> <li>Pneumococcal vaccine(s)</li> <li>RZV</li> </ul> </td> <td> <ul> <li>Fingolimod should not be used with natalizumab due to increased risk of PML.</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table serves as an overview of how to evaluate for and prevent infections in patients starting and/or taking anti-integrin monoclonal antibodies and S1P receptor modulators. Infections highlighted in <strong>bold</strong> have been specifically associated with the biologic agent and warrant extra consideration.</div><div class="graphic_footnotes"><p>CMV: cytomegalovirus; CNS: central nervous system; EBV: Epstein-Barr virus; HBV: hepatitis B virus; HCV: hepatitis C virus; HHV-8: human herpesvirus 8; HIV: human immunodeficiency virus; HSV: herpes simplex virus; JCV: John Cunningham virus; LTBI: latent tuberculosis infection; MAdCAM-1: mucosal vascular addressin cell adhesion molecule 1; PML: progressive multifocal leukoencephalopathy; RZV: recombinant (non-live) zoster vaccine (Shingrix); S1P: sphingosine-1-phosphate; TBI: tuberculosis infection; VCAM: vascular cell adhesion protein.</p>
<p>* In addition to the infections listed, typical, common bacterial and viral infections should also be considered in the differential when infection is suspected in a patient taking the specified agent.</p>
<p>¶ For patients who do not have a negative HIV test documented in their records or are at increased risk of acquiring HIV (eg, men who have sex with men, engagement in sex work), the pre-treatment infectious testing process is a good opportunity to provide routine HIV screening prior to the initiation of immunosuppression. Treat any latent or active infections found on pre treatment testing. Control of infection should be demonstrated prior to initiating immunosuppressive therapy.</p>
<p>Δ Live and non-live vaccines should be administered no later than 4 and 2 weeks, respectively, prior to initiating therapy. Vaccine responses may be attenuated while on therapy.</p>
<p>◊ We also obtain baseline magnetic resonance imaging of the brain prior to initiating therapy with natalizumab.</p>
<p>§ Other S1P receptor modulators (eg, siponimod, ozanimod) should be managed like fingolimod.</p>
¥ Some clinicians opt to test for JCV similar to the approach used for patients starting natalizumab; however, this is not routine among all clinicians.</div><div id="graphicVersion">Graphic 143345 Version 1.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
